Search Results

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test.

The Alberta Cancer Foundation, Alberta Health Services and the University of Calgary are thrilled to announce a historic and transformational $50 million donation to the Calgary Cancer Centre from the Arthur J.E. Child Foundation.

Adhera Therapeutics, Inc. (OTCQB: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (“ADI”) at the University of Alberta (“U of A”), located in Edmonton, Alberta, Canada.

The Alberta Cancer Foundation is thrilled to announce that Entos Pharmaceuticals and 48Hour Discovery are the first recipients of its new Breakthrough Fund, an innovative, philanthropic vehicle that will support important research opportunities with the potential to accelerate cancer care and treatment through to commercialization.

Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.